undamentalytics Newsletter
Sign in

Olema Pharmaceuticals, Inc. (OLMA) stock

Add to watchlist

Add holding +

NASDAQ: OLMA Nasdaq Biotechnology Next results ~November 9, 2026

Olema Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 6 selling0 purchases and 25 sales by directors and officers, last 12 monthsInsider trades
  • Funds94 adding, 93 cuttingOf 46 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 8% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Olema Pharmaceuticals, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 153% and a beta of 0.5 against the S&P 500.
  • Insiders selling. 6 insiders sold $25M of stock over the past 365 days and none bought (0% under pre-set trading plans).
  • Heavily shorted. 21.8% of the shares available to trade are sold short (11.7 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$0.61 against an average estimate of -$0.56: missed by 8.2%
Share reaction
-13.4% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$0.63

Olema Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.0%
  • 1 week+6.8%
  • 1 month-14.0%
  • This year-71.7%
  • 1 year-21.2%
  • 5 years-74.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 10, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Leadership
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Olema Pharmaceuticals, Inc. valuation models and calculator

No model value for Olema Pharmaceuticals, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.63 (range −$0.73 to −$0.50) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.38 −27% — 0%
Next −$2.64 −11% $6m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.6% on 90 days ago. In the last 30 days, 1 analyst raised Olema Pharmaceuticals, Inc.'s forecast and 7 cut it.

Consensus EPS forecast Olema Pharmaceuticals, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.27 Current fiscal year, 60 days ago: −$2.27 Current fiscal year, 30 days ago: −$2.42 Current fiscal year, 7 days ago: −$2.37 Current fiscal year, Now: −$2.38 −$2.38 Next fiscal year, 90 days ago: −$2.48 Next fiscal year, 60 days ago: −$2.48 Next fiscal year, 30 days ago: −$2.69 Next fiscal year, 7 days ago: −$2.67 Next fiscal year, Now: −$2.64 −$2.64

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.27−$2.48
60 days ago −$2.27−$2.48
30 days ago −$2.42−$2.69
7 days ago −$2.37−$2.67
Now −$2.38−$2.64

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.56 −$0.61 −8.2%
Mar 2026 −$0.54 −$0.52 +3.5%
Dec 2025 −$0.53 −$0.50 +5.1%
Sept 2025 −$0.45 −$0.49 −8.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

12 analysts, Oct 2026
Buy1192%
Hold18%
Sell00%

Monthly trend

  1. Oct 202629112
  2. Sep 202629112
  3. Aug 202629112

Counts of recommendations published by analysts covering Olema Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
21.8%
of tradable shares
Days to cover
11.68
at average volume
Short interest, 1 month
−2%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.8%
of shares
Employees
150
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
OLMA−81%−74%+473%−58%+329%−72%
Industry peers (median)−35%−56%−18%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
OLMA25%33%75%25%58%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
OLMA−84%−78%−35%−66%−54%−78%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 19, 2020: 96% from December 1, 2020 to May 11, 2022. Getting back needed a 2572% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$6.41 – $35.83
From 52-week high
−80.3%
vs 50-day average
−19.3%
vs 200-day average
−49.2%
Volatility (1 year)
153%
Beta vs S&P 500
0.48

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±7.7%
After a week
3 up, 9 down
typical move ±11.6%
After a month
4 up, 8 down
typical move ±43.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −13.4% −0.3% −10.6% −14.0%
May 12, 2026 −8.6% +0.4% −11.8% −34.4%
March 16, 2026 +2.3% +1.3% −5.0% +12.1%
January 12, 2026 −0.7% 0.0% −4.8% −15.8%
November 10, 2025 −1.9% +1.8% +2.0% +267.4%
August 11, 2025 +14.4% +0.9% +24.1% +68.3%
May 13, 2025 −5.5% +0.8% +6.7% −14.7%
March 18, 2025 −7.6% 0.0% −5.8% −4.3%
November 12, 2024 −9.7% −0.3% −31.4% −47.2%
August 6, 2024 −9.4% +0.2% −9.7% −14.7%
May 8, 2024 −12.5% +0.6% −12.4% +16.8%
March 11, 2024 −6.6% +1.0% −14.8% −15.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$1.3B
Institutions reporting
183
Shares held vs prior quarter
▲ 0.4%
Positions opened / closed
22 / 33

Top buyers and sellers, Q2 2026: 94 institutions bought and 93 sold ; the biggest buyer was FMR LLC (+1.8M shares) and the biggest seller RA Capital Management, L.P (−2.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $152M 12.1M 11.9% ▲ 16.9%
Paradigm Biocapital Advisors LP $108M 8.7M 8.5% ▲ 8.1%
Jupiter Topco LLC $88.8M 7.1M 7.0% —
Bain Capital Life Sciences Investors, LLC $88.6M 7.1M 7.0% ▼ 5.2%
Blackrock, Inc. $84M 6.7M 6.6% ▲ 18.8%
Bvf Inc $66.3M 5.3M 5.2% 0.0%
Siren, L.L.C. $60.8M 4.9M 4.8% ▲ 2.1%
State Street Corp $54M 4.3M 4.2% ▲ 9.6%
Vanguard Capital Management LLC $41.8M 3.3M 3.3% ▲ 8.4%
Logos Global Management LP $40.1M 3.2M 3.1% 0.0%
Franklin Resources Inc $29.4M 2.3M 2.3% ▲ 92.8%
Cormorant Asset Management, LP $26.9M 2.1M 2.1% ▼ 44.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Olema Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $24.7M 25 trades by 6 insiders · 0% under pre-set plans
Net ▼ $24.7M net selling
Insider Date Trade Shares Price Value
Harmon Cyrus Director July 24, 2026 Sell 12,500 $11.71 $146,375
Harmon Cyrus Director July 23, 2026 Sell 12,500 $11.58 $144,750
Mitchell Shawnte CHIEF LEGAL OFFICER March 4, 2026 Sell 24,767 $24.25 $600,600
Mitchell Shawnte CHIEF LEGAL OFFICER March 4, 2026 Sell 233 $24.69 $5,753
Mitchell Shawnte CHIEF LEGAL OFFICER March 3, 2026 Sell 15,000 $23.01 $345,150
Harmon Cyrus Director January 20, 2026 Sell 10,000 $26.88 $268,800
Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. January 15, 2026 Sell 100,000 $28.73 $2.9M
Myles David C. CH. DISCOV. & NON-CLIN DEV OFF January 14, 2026 Sell 35,003 $28.99 $1M
Myles David C. CH. DISCOV. & NON-CLIN DEV OFF January 14, 2026 Sell 14,997 $28.60 $428,914
Harmon Cyrus Director January 14, 2026 Sell 3,489 $29.12 $101,600
Myles David C. CH. DISCOV. & NON-CLIN DEV OFF January 13, 2026 Sell 200 $28.49 $5,698
Myles David C. CH. DISCOV. & NON-CLIN DEV OFF January 13, 2026 Sell 49,800 $27.60 $1.4M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 26, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 12, 2026
  • March 16, 2026
  • January 12, 2026
  • November 10, 2025
  • August 11, 2025

Recent SEC filings

Data status

When each part of this page on Olema Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Olema Pharmaceuticals, Inc. in brief

What does Olema Pharmaceuticals, Inc. do?
Olema Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Olema Pharmaceuticals, Inc.'s stock ticker?
Olema Pharmaceuticals, Inc. trades under the ticker OLMA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Olema Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Paradigm Biocapital Advisors LP and Jupiter Topco LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Olema Pharmaceuticals, Inc. stock?
Over the last 12 months, Olema Pharmaceuticals, Inc.'s directors and officers reported 0 open-market purchases and 25 sales on Form 4. The insider trading page charts every trade.
When is Olema Pharmaceuticals, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Olema Pharmaceuticals, Inc. announces its own schedule.